Viridian Therapeutics (NASDAQ:VRDN) Stock Price Target Raised at Wedbush

Viridian Therapeutics (NASDAQ:VRDN) had its target price hoisted by equities researchers at Wedbush from $41.00 to $42.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush‘s price target indicates a potential upside of 44.53% from the stock’s previous close.

Other research analysts have also issued research reports about the stock. Needham & Company LLC upped their price target on shares of Viridian Therapeutics from $34.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen downgraded shares of Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Royal Bank Of Canada boosted their price objective on Viridian Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Tuesday, September 22nd. Weiss Ratings raised Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 14th. Finally, HC Wainwright upped their target price on Viridian Therapeutics from $22.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Viridian Therapeutics Stock Performance

NASDAQ VRDN opened at $29.06 on Thursday. The firm has a market capitalization of $3.29 billion, a P/E ratio of -8.62 and a beta of 1.07. The firm’s fifty day moving average price is $21.80 and its two-hundred day moving average price is $21.85. Viridian Therapeutics has a 1 year low of $13.18 and a 1 year high of $34.29. The company has a current ratio of 16.95, a quick ratio of 16.95 and a debt-to-equity ratio of 0.43.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.21. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. The business had revenue of $25.75 million during the quarter, compared to the consensus estimate of $4.72 million. As a group, research analysts anticipate that Viridian Therapeutics will post -4.07 EPS for the current year.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 14,212 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total transaction of $348,194.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Viridian Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP increased its holdings in Viridian Therapeutics by 1.6% in the 2nd quarter. Wellington Management Group LLP now owns 3,128,362 shares of the company’s stock valued at $57,468,000 after buying an additional 49,808 shares during the period. Parkman Healthcare Partners LLC bought a new stake in shares of Viridian Therapeutics during the 2nd quarter worth approximately $25,306,000. Rice Hall James & Associates LLC bought a new stake in shares of Viridian Therapeutics during the 2nd quarter worth approximately $21,601,000. Bank of America Corp DE boosted its position in shares of Viridian Therapeutics by 17.5% during the 1st quarter. Bank of America Corp DE now owns 1,163,615 shares of the company’s stock worth $22,760,000 after acquiring an additional 173,498 shares in the last quarter. Finally, Elmind Capital LP acquired a new stake in shares of Viridian Therapeutics during the 2nd quarter worth approximately $18,093,182.

More Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Viridian reported a Q3 loss of $0.81 per share, narrower than analysts’ expected loss of $1.01–$1.02. Revenue of $25.75 million also exceeded the roughly $4.72 million consensus estimate. The EPS loss was nevertheless wider than the $0.34 loss a year earlier. Viridian Q3 results
• Positive Sentiment: Management signaled it is targeting a biologics license application for elegrobart in Q1 2027 and expects Lumvoa’s launch to reach broad coverage within six to nine months—milestones that could strengthen the commercial and pipeline outlook. Elegrobart and Lumvoa outlook
• Positive Sentiment: Needham raised its price target to $38 from $34 and maintained a Buy rating, reflecting a more optimistic analyst view of VRDN’s prospects. Needham price target update
• Negative Sentiment: A Yahoo Finance commentary said VRDN looks overvalued even with its new launch, highlighting valuation as a potential concern after the stock’s strong performance. Valuation commentary

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.